Legal & General Group PLC Autolus Therapeutics PLC Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Legal & General Group PLC holds 60,512 shares of AUTL stock, worth $138,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,512

Previous 60,512 -0.0%

Holding current value

$138,572

Previous $219,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.33 - $5.68 $201,504 - $343,708	60,512 New	60,512 $210,000
Q2 2022 Aug 22, 2022	BUY	$2.04 - $4.68 $71,018 - $162,924	34,813 Added 106.45%	67,517 $192,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $18,972 - $26,040	3,720 Added 12.83%	32,704 $170,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $40,682 - $56,358	7,647 Added 35.84%	28,984 $190,000
Q2 2021 Aug 12, 2021	BUY	$4.78 - $7.96 $49,931 - $83,150	10,446 Added 95.91%	21,337 $142,000
Q4 2020 Feb 12, 2021	BUY	$8.13 - $12.79 $18,138 - $28,534	2,231 Added 25.76%	10,891 $97,000
Q2 2020 Aug 14, 2020	BUY	$5.38 - $16.14 $21,719 - $65,157	4,037 Added 87.32%	8,660 $138,000
Q1 2020 May 14, 2020	BUY	$4.2 - $13.0 $4,653 - $14,404	1,108 Added 31.52%	4,623 $27,000
Q4 2019 Feb 13, 2020	BUY	$11.13 - $16.28 $37,496 - $54,847	3,369 Added 2307.53%	3,515 $46,000
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $1,510 - $3,125	100 Added 217.39%	146 $2,000
Q4 2018 Feb 15, 2019	BUY	$24.21 - $48.01 $1,113 - $2,208	46 New	46 $1,000

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Autolus Therapeutics PLC Transaction History